Daily subcutaneous (s.c.) pretreatment with morphine-3-glucuronide (6 mg/kg) was found to reduce morphine-6-glucuronide (4 mg/kg s.c.)-induced antinociception, with no decrease in the effect over 5 days. Morphine-6-glucuronide administration (4 mg/kg s.c.) on Day 6, without morphine-3-glucorinide pretreatment, results in a significant increase in antinociception (from 24% on Day 5 to 70%; p< or =0.05). Morphine-3-glucuronide may prevent tolerance to morphine-6-glucuronide by reducing morphine-6-glucuronide-induced antinociception.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1090-3801(97)90074-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics and thermal anti-nociceptive effects of oral morphine in horses.
Front Vet Sci
September 2024
Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.
Article Synopsis
- Morphine is effective for pain relief in horses, but intravenous (IV) use can cause unwanted side effects like neuroexcitation and gastrointestinal issues.
- Oral administration of morphine yields similar pain-relief potential through the metabolite M6G without the negative effects of IV administration.
- The study found that oral morphine doses provided effective pain relief comparable to IV morphine while causing less excitation and gastrointestinal disturbances, indicating the need for further research.
Development and validation of an LC-MS/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma.
J Chromatogr B Analyt Technol Biomed Life Sci
April 2024
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Institute of Forensic Medicine, Department of Biomedical Engineering, University of Basel, Basel, Switzerland; Institute of Forensic Medicine, Health Department Basel-Stadt, Basel, Switzerland.
Diamorphine, commonly known as heroin, is a semi-synthetic opioid analgesic. In the context of heroin-assisted treatment for opioid-dependent patients, diamorphine is mostly administered intravenously. However, recent attention has shifted towards intranasal administration as a better-tolerated alternative to the intravenous route.
View Article and Find Full Text PDFOpioid MOP receptor agonists in late-stage development for the treatment of postoperative pain.
Expert Opin Pharmacother
November 2022
Department of Anaesthesiology, The University of Hong Kong, Special Administrative Region, Hong Kong, Kwai Tsing, China.
Introduction: Opioids remain important in postoperative analgesia although, the focus is on using them as part of multimodal regimens where it is not possible to avoid their use completely. The development of novel agents with more favorable adverse effect profiles may increase safety whilst maintaining efficacy.
Areas Covered: This article reviews the clinical trials for opioids in late-stage development.
Pharmacokinetics, adverse effects and effects on thermal nociception following administration of three doses of codeine to horses.
BMC Vet Res
May 2022
K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, CA, 95616, USA.
Background: In humans, codeine is a commonly prescribed analgesic that produces its therapeutic effect largely through metabolism to morphine. In some species, analgesic effects of morphine have also been attributed to the morphine-6-glucuronide (M6G) metabolite. Although an effective analgesic, administration of morphine to horses produces dose-dependent neuroexcitation at therapeutic doses.
View Article and Find Full Text PDFDeep proteomics and phosphoproteomics reveal novel biological pathways perturbed by morphine, morphine-3-glucuronide and morphine-6-glucuronide in human astrocytes.
J Neurosci Res
January 2022
Department of Medicine, University of Geneva, Geneva, Switzerland.
Tolerance and hyperalgesia associated with chronic exposure to morphine are major limitations in the clinical management of chronic pain. At a cellular level, neuronal signaling can in part account for these undesired side effects, but unknown mechanisms mediated by central nervous system glial cells are likely also involved. Here we applied data-independent acquisition mass spectrometry to perform a deep proteome and phosphoproteome analysis of how human astrocytes responds to opioid stimulation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!